Advances in immunopharmacology of asthma (Q33883632)

29 July 2017

1 reference

title

Advances in immunopharmacology of asthma (English)

1 reference

29 July 2017

1 reference

Wong WS

1

1 reference

29 July 2017

Koh DS

series ordinal

2

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 June 2000

1 reference

29 July 2017

published in

Biochemical Pharmacology

1 reference

29 July 2017

volume

59

1 reference

29 July 2017

issue

11

1 reference

29 July 2017

page(s)

1323-1335

1 reference

The inverse association between tuberculin responses and atopic disorder.

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

One explanation of the asthma paradox: inhibition of natural anti-inflammatory mechanism by beta 2-agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Pathophysiology of asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

TH2 and 'TH2-like' cells in allergy and asthma: pharmacological perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Infiltration of eosinophils into the asthmatic airways caused by interleukin 5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Therapeutic uses of heparin beyond its traditional role as an anticoagulant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Phosphodiesterase isozymes: molecular targets for novel antiasthma agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Signal transduction by immunoglobulin Fc receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Jaks, Stats and the Immune System

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

NF-kB: a pivotal role in asthma and a new target for therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Biology of IL-5 in health and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Effect of Inhaled Interleukin-4 on Airway Hyperreactivity in Asthmatics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against "intrinsic" asthma being a distinct immunopathologic entity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Membrane-bound and soluble alpha IL-5 receptor mRNA in the bronchial mucosa of atopic and nonatopic asthmatics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Clinical significance of measuring levels of sputum and serum ECP and serum IL-5 in bronchial asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

An interleukin 4 (IL-4) mutant protein inhibits both IL-4 or IL-13-induced human immunoglobulin G4 (IgG4) and IgE synthesis and B cell proliferation: support for a common component shared by IL-4 and IL-13 receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Identification of receptor-binding domains on human interleukin 5 and design of an interleukin 5-derived receptor antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

An interleukin 5 mutant distinguishes between two functional responses in human eosinophils.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Time course study for antigen-induced airway hyperreactivity and the effect of soluble IL-5 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Effect of anti-IL-4 and anti-IL-5 antibodies on allergic airway hyperresponsiveness in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Anti‐interleukin (IL)‐4 and ‐IL‐5 antibodies downregulate IgE and eosinophilia in mice exposed to Aspergillus antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Effects of chronic anti-interleukin-5 monoclonal antibody treatment in a murine model of pulmonary inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Inhibition of pulmonary eosinophilia and hyperreactivity by antibodies to interleukin-5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Relation between Airway Responsiveness and Serum IgE in Children with Asthma and in Apparently Normal Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

IgE enhances mouse mast cell Fc(epsilon)RI expression in vitro and in vivo: evidence for a novel amplification mechanism in IgE-dependent reactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

IgE-dependent antigen focusing by human B lymphocytes is mediated by the low-affinity receptor for IgE.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: inhibition by a non-anaphylactogenic anti-IgE antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Therapeutic potential of anti-IgE antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Demonstration of the therapeutic potential of non-anaphylactogenic anti-IgE antibodies in murine models of skin reaction, lung function and inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Effect of heparin and a low‐molecular weight heparinoid on PAF‐induced airway responses in neonatally immunized rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Effect of inhaled heparin on allergen-induced early and late asthmatic responses in patients with atopic asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Time course of the protective effect of inhaled heparin on exercise-induced asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Inhibition of serum and transforming growth factor beta (TGF-beta1)-induced DNA synthesis in confluent airway smooth muscle by heparin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Interaction of Secretory Leukocyte Protease Inhibitor with Heparin Inhibits Proteases Involved in Asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Interleukin 4 production by human amnion epithelial cells and regulation of its activity by glycosaminoglycan binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Heparin prevents antigen-induced airway hyperresponsiveness: interference with IP3-mediated mast cell degranulation?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Inhibition of Antigen-induced Airway Hyperresponsiveness by Ultralow Molecular-weight Heparin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Molecular-weight-dependent effects of nonanticoagulant heparins on allergic airway responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Inhibition of antigen-induced acute bronchoconstriction, airway hyperresponsiveness, and mast cell degranulation by a nonanticoagulant heparin: comparison with a low molecular weight heparin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Salbutamol inhibits the proliferation of human airway smooth muscle cells grown in culture: relationship to elevated cAMP levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

PKA isoforms, neural pathways, and behaviour: making the connection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Emetic, central nervous system, and pulmonary activities of rolipram in the dog.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP‐specific phosphodiesterase: comparison with rolipram

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Effect of the glucocorticosteroid budesonide and a novel phosphodiesterase type 4 inhibitor CDP840 on antigen-induced airway responses in neonatally immunised rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Leukocyte protein tyrosine kinases: potential targets for drug discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Tyrosine kinases in activation of the MAP kinase cascade by G-protein-coupled receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

RANTES induces tyrosine kinase activity of stably complexed p125FAK and ZAP-70 in human T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Temporal activation of nontransmembrane protein-tyrosine kinases following mast cell Fc epsilon RI engagement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Involvement of Bruton's tyrosine kinase in FcepsilonRI-dependent mast cell degranulation and cytokine production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Fc epsilon R1-mediated tyrosine phosphorylation of multiple proteins, including phospholipase C gamma 1 and the receptor beta gamma 2 complex, in RBL-2H3 rat basophilic leukemia cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Mitogen-activated protein (MAP) kinase regulates production of tumor necrosis factor-alpha and release of arachidonic acid in mast cells. Indications of communication between p38 and p42 MAP kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Role of Tyrosine Kinases in IgE-mediated Signal Transduction in Human Lung Mast Cells and Basophils

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Effects of mitogen-activated protein kinase kinase inhibitor PD 098059 on antigen challenge of guinea-pig airways in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

ER-27319, an acridone-related compound, inhibits release of antigen-induced allergic mediators from mast cells by selective inhibition of Fcɛ receptor I-mediated activation of Syk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Src family‐selective tyrosine kinase inhibitor, PP1, inhibits both FcεRI‐ and Thy‐1‐mediated activation of rat basophilic leukemia cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Terreic acid, a quinone epoxide inhibitor of Bruton's tyrosine kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Modulation of normal human eosinophil chemotaxis in vitro by herbimycin A, erbstatin and pervanadate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Role of the mitogen-activated protein kinases and tyrosine kinases during leukotriene B4-induced eosinophil activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Essential role of Stat6 in IL-4 signalling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Signal Transducer and Activator of Transcription Factor 6 (Stat6)-deficient Mice Are Protected from Antigen-induced Airway Hyperresponsiveness and Mucus Production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Protein Kinase InhibitorsThe Tyrosine-Specific Protein Kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

The allergen Der p1 induces NF-kappaB activation through interference with IkappaB alpha function in asthmatic bronchial epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Activation and localization of transcription factor, nuclear factor-kappaB, in asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Essential role of nuclear factor kappaB in the induction of eosinophilia in allergic airway inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Molecular mechanisms of steroid action in asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Cross-talk between steroids and NF-κB: what language?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Calcineurin acts in synergy with PMA to inactivate I kappa B/MAD3, an inhibitor of NF-kappa B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF‐κB activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappaB transcriptional activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

4-trifluoromethyl derivatives of salicylate, triflusal and its main metabolite 2-hydroxy-4-trifluoromethylbenzoic acid, are potent inhibitors of nuclear factor kappaB activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-kappaB.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

The anti-inflammatory sesquiterpene lactone helenalin inhibits the transcription factor NF-kappaB by directly targeting p65

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Helenalin, an anti-inflammatory sesquiterpene lactone from Arnica, selectively inhibits transcription factor NF-kappaB

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Inhibition of NF-kappa-B cellular function via specific targeting of the I-kappa-B-ubiquitin ligase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Inhibition of TNF- α -induced NF- κ B Activation and IL-8 Release in A549 Cells with the Proteasome Inhibitor MG-132

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Asthma therapy for the 21st century

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

DNA antisense therapy for asthma in an animal model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Neuropeptides and asthma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

The kinin system in rhinitis and asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Effect of YM934, a novel potassium-channel opener, in various experimental asthma models in guinea-pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Suppression of metalloproteinase biosynthesis in human alveolar macrophages by interleukin-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

New concepts of IgE regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(99)00378-0

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-2952(99)00378-0

1 reference

29 July 2017

1 reference